Genetic Polymorphisms in Genes Related to Oxidative Stress (GSTP1, GSTM1, GSTT1, CAT, MnSOD, MPO, eNOS) and Survival of Rectal Cancer Patients after Radiotherapy
Table 3
Hazard ratios of overall mortality in rectal cancer patients who received radiation therapy according to polymorphisms in GSTP1, GSTT1, GSTM1, CAT, MnSOD, MPO, and eNOS.
Genetic polymorphism
N Cases/Deaths
Person-years
Death/Person-years
(95% CI)
GSTP1
Ile/Ile
54/16
194.5
0.08
1
Ile/Val
51/17
174.3
0.10
1.18
(0.58–2.40)
Val/Val
9/2
33.0
0.06
.75
0.85
(0.19–3.85)
.88
Val carriers
1.14
(0.57–2.28)
GSTM1
nonnull
61/16
218.0
0.07
1
null
53/19
183.8
0.10
.35
1.64
(0.84–3.21)
.15
GSTT1
nonnull
91/31
321.5
0.10
1
null
23/4
80.3
0.05
.17
0.68
(0.23–2.00)
.49
CAT
C/C
65/20
225.2
0.09
1
C/T
43/13
156.4
0.08
1.37
(0.65–2.87)
T/T
6/2
20.1
0.10
.96
0.58
(0.13–2.71)
.98
T carriers
1.16
(0.58–2.30)
MnSOD
Val/Val
25/8
96.6
0.08
1
Val/Ala
67/20
230.7
0.09
0.76
(0.31–1.85)
Ala/Ala
20/7
68.5
0.10
.93
0.83
(0.27–2.51)
.75
Ala carriers
0.78
(0.33–1.84)
MPO
G/G
64/25
207.2
0.12
1
G/A
43/8
172.2
0.05
0.39
(0.17–0.87)
A/A
7/2
22.5
0.09
.06
1.12
(0.25–5.08)
.09
A carriers
0.44
(0.21–0.93)
eNOS
Glu/Glu
51/12
194.7
0.06
1
Glu/Asp
53/20
175.5
0.11
2.19
(1.04–4.61)
Asp/Asp
10/3
31.7
0.09
.29
1.56
(0.41–6.01)
.12
Asp carriers
2.10
(1.01–4.38)
ox proportional hazards model adjusted for sex, study, and cancer stage.
